Neurofibromatosis Type 1. Clinical Case
DOI:
https://doi.org/10.61788/njn.v1i23.08Keywords:
neurofibromatosis, diagnosis, clinical criteriaAbstract
The relevance of the topic covered in the article is related to the fact that doctors have little knowledge about this nosology. For this reason, a timely and incorrect diagnosis can result in wrong treatment, reduce the patient's quality of life and even lead to death. The diagnosis of the patient we investigated was determined according to the clinical criteria developed by the National Institute of Health of the United States. If genetic examination is not performed, the established diagnosis can be considered justified. It is imperative that several medical professionals (neurologist, traumatologist, ophthalmologist, surgeon, pediatrician, gynecologist, etc.) are aware of a disease like neurofibromatosis (NF). Basing on the clinical criteria developed by the US National Institutes of Health provides favorable conditions for diagnosing patients.
References
Дядькин В.Ю. Случай локализованной формы нейрофиброматоза I типа // Практическаямедицина. - 2013. - № 1-4. - С. 130-131.
Зайдман А.М., Михайловский М.В., Завьялова Е.Л. и др. Структурно-функциональные особенности деформации позвоночника при нейрофиброматозе 1-го типа // Бюллетень сибирской медицины. - 2010. - № 6 (9). - С. 34-40.
Конторович А.К., Гусарев С.А. Нейрофиброматоз брюшной полости // Молодой ученый. - 2016. - № 15. - С. 15-17.
Banerjee S., Byrd J.N., Gianino S.M., et al. The neurofibromatosis type 1 tumor suppressor controls cell growth by regulating signal transducer and activator of transcription-3 activity in vitro and in vivo // Cancer Research. - 2010. - Vol. 70 (4). - P. 1356-1366. - doi:10.1158/0008- 5472CAN-09-2178.
Карандашева К.О., Пащенко М.С., Дёмина Н.А., Акимова И.А., и др. Соматический мозаицизм при нейрофиброматозе первого типа // Медицинская генетика. 2019;18(5):28- 36. https://doi.org/10.25557/2073-7998.2019.05.28-36
Коновалов Н.А., Королишин В.А., Асютин Д.С., Тимонин С.Ю., и др. Лечение злокачественных опухолей оболочек периферических нервов: случаи из практики и обзор литературы // Журнал «Вопросы нейрохирургии» имени Н.Н. Бурденко 2019;83(3):64-72. doi: 10.17116/ neiro20198303164.
de Vasconcelos R.A.T., Coscarelli P.G., Alvarenga R.P., Acioly M.A. Malignant peripheral nerve sheath tumor with and without neurofi bromatosis type 1 // Arq Neuropsiquiatr 2017;75(6):366-71. doi: 10.1590/0004-282X20170052.
Uusitalo E., Kallionpää R.A., Kurki S., Rantanen M., et al. Breast cancer in neurofi bromatosis type 1: overrepresentation of unfavourable prognostic factors // Br J Cancer 2017;116(2):211-7. doi: 10.1038/bjc.2016.403.
Landry J.P., Schertz K.L., Chiang Y.-J., Bhalla A.D., et al. Comparison of Cancer Prevalence in Patients with Neurofibromatosis Type 1 at an Academic Cancer Center vs in the General Population from 1985 to 2020 // JAMA Netw Open 2021;4(3): e210945. doi: 10.1001/jamanetworkopen.2021.0945.
United States Department of Health and Human Services (The National Institute of Health): The diagnostic criteria for NF-1. [Electronic resource]: https://consensus.nih.gov/1987/1987Neurofibramatosis064html.htm (appeal date 11.05.2021).
Korf B.R., Lobbous M., Metrock L.K. Neurofibromatosis type 1 (NF1): Management and prognosis. UpToDate. Waltham, MA: Up to Date. Retrieved from www. uptodate. com (2017). UpToDate.
Ross A.L., Panthaki Z., Levi A.D. Surgical management of a giant plexiform neurofi broma of the lower extremity // World Neurosurg 2011;75(5-6):754-7. doi: 10.1016/j.wneu.2010.09.030.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2026 National Association of Neurologists
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
